Profound Medical Corp

Profound Medical Corp has a highly liquid capital structure, with a current ratio of 12.52, indicating strong short-term liquidity. However, the company has negative operating and free cash flows, with operating cash flow at -38.2 million USD and free cash flow at -42.3 million USD, which suggests ongoing cash burn. The company's debt-to-equity ratio is low at 0.07, and total liabilities are only 11.0 million USD compared to total equity of 66.4 million USD, indicating a conservative leverage profile. The company's profitability metrics are weak, with a return on equity of -64.08% and a return on assets of -54.95%. These figures are significantly below the industry median for profitability in the Advanced Medical Equipment & Technology sector, which typically sees positive returns on equity and assets. The company's operating income is negative at -41.3 million USD, and net income is also negative at -42.6 million USD, indicating that the company is not yet generating sustainable earnings. Geographically, the company's revenue is not disclosed by region, but it is primarily focused on the North American market, as indicated by its regulatory filings and commercial operations. The company has not disclosed segment-specific revenue figures, but its operations are concentrated in the development and commercialization of neuromodulation therapies. This concentration may expose the company to regulatory and reimbursement risks in key markets. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The company is in a pre-revenue or early-revenue phase, and its outlook for the next fiscal year is not quantified in the available data. The company's operating losses and negative cash flows suggest that it is still in the investment phase, with no clear path to profitability in the near term. The company faces several risk factors, including liquidity risk due to negative operating and free cash flows, and the potential for dilution if the company raises additional capital. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's net cash position is negative after subtracting total debt. The company has not disclosed any recent equity issuances or dilution events, but the risk of future dilution remains if the company requires additional financing. Recent events include the company's continued focus on clinical trials and regulatory approvals for its neuromodulation therapies. The company has not disclosed any recent earnings calls or investor presentations, but its financial statements indicate ongoing investment in research and development. The company's price targets from analysts are all set at 11.50 USD, with a mean recommendation of 2.00, indicating a cautious outlook from the analyst community.